We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HTBK
2001
DELISTED
Heritage Commerce
HTBK
| $194K | ﹤0.01% |
18,157
+2,013
| +12% | +$22.5K |
|
2002
Concrete Pumping Holdings
BBCP
$473M
| $189K | ﹤0.01% |
31,269
-4,370
| -12% | -$24.8K |
|
2003
Crinetics Pharmaceuticals
CRNX
$8.93B
| $189K | ﹤0.01% |
10,138
-16,268
| -62% | -$325K |
|
2004
Ardmore Shipping
ASC
$670M
| $188K | ﹤0.01% |
+26,945
| New | +$180K |
|
|
XRN
2005
Chiron Real Estate Inc
XRN
$475M
| $187K | ﹤0.01% |
+3,335
| New | +$225K |
|
|
DVAX
2006
DELISTED
Dynavax Technologies
DVAX
| $185K | ﹤0.01% |
14,695
-5,844
| -28% | -$62.1K |
|
2007
Uranium Energy
UEC
$5.63B
| $185K | ﹤0.01% |
60,129
+13
| +0% | +$54 |
|
|
XHR
2008
Xenia Hotels & Resorts
XHR
$1.74B
| $181K | ﹤0.01% |
12,489
+1,553
| +14% | +$27.7K |
|
2009
Adtran
ADTN
$622M
| $179K | ﹤0.01% |
10,231
-39
| -0.4% | -$706 |
|
|
PSTL
2010
Postal Realty Trust
PSTL
$680M
| $177K | ﹤0.01% |
11,864
+1,196
| +11% | +$19.1K |
|
2011
Energy Fuels
UUUU
$3.57B
| $175K | ﹤0.01% |
35,725
| – | – |
|
2012
Vertex
VERX
$1.97B
| $172K | ﹤0.01% |
+15,200
| New | +$192K |
|
2013
Kodiak Sciences
KOD
$2.72B
| $170K | ﹤0.01% |
22,220
-16,191
| -42% | -$114K |
|
|
ACCD
2014
DELISTED
Accolade Inc
ACCD
| $169K | ﹤0.01% |
+22,852
| New | +$200K |
|
2015
MBIA
MBI
$256M
| $166K | ﹤0.01% |
+13,474
| New | +$177K |
|
|
AIV
2016
Aimco
AIV
$377M
| $165K | ﹤0.01% |
26,991
+1,359
| +5% | +$8.57K |
|
|
CARM
2017
DELISTED
Carisma Therapeutics
CARM
| $164K | ﹤0.01% |
10,096
+8,431
| +506% | +$96.5K |
|
2018
Aldeyra Therapeutics
ALDX
$91.1M
| $163K | ﹤0.01% |
+40,954
| New | +$141K |
|
2019
OraSure Technologies
OSUR
$275M
| $163K | ﹤0.01% |
+60,209
| New | +$299K |
|
2020
Veritone
VERI
$134M
| $163K | ﹤0.01% |
+24,975
| New | +$252K |
|
2021
Riot Platforms
RIOT
$7.34B
| $162K | ﹤0.01% |
+38,730
| New | +$360K |
|
|
TVRD
2022
Tvardi Therapeutics
TVRD
$22M
| $160K | ﹤0.01% |
485
-708
| -59% | -$248K |
|
2023
Blue Owl Capital
OWL
$18.2B
| $159K | ﹤0.01% |
+15,895
| New | +$191K |
|
2024
Globalstar
GSAT
$10.9B
| $158K | ﹤0.01% |
8,571
+2,343
| +38% | +$43.5K |
|
2025
AquaBounty Technologies
AQB
$7.05M
| $157K | ﹤0.01% |
4,581
+2,195
| +92% | +$67K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.